Evidence-based review of topical treatments for psoriasis

Advanced Studies in Medicine

Volumn 4, Issue 8, 2004, Pages 420-429

  Mikhail, Maryann ^a   Scheinfeld, Noah ^b,c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Howard Hughes Medical Institute   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; DHS TAR; DITHRANOL; DOCTAR; EMOLLIENT AGENT; HLA B ANTIGEN; HLA B13 ANTIGEN; HLA B17 ANTIGEN; HLA CW6 ANTIGEN; KERATOLYTIC AGENT; MOCLOBEMIDE; MOMETASONE FUROATE; RETINOL DERIVATIVE; SALICYLIC ACID DERIVATIVE; TAZAROTENE; TAZOREC; THERAPLEX T; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; BODY SURFACE; BURNING SENSATION; CLINICAL FEATURE; CORTICOSTEROID BLOOD LEVEL; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; ERYTHEMA; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPIGMENTATION; INFECTION; MAINTENANCE THERAPY; MENTAL DISEASE; PATHOPHYSIOLOGY; PRURITUS; PSORIASIS; RADIATION EXPOSURE; REBOUND; REMISSION; REVIEW; SIDE EFFECT; SKIN IRRITATION; SKIN THINNING; STRESS; STRIA; TACHYPHYLAXIS; TINNITUS; TREATMENT INDICATION; ULTRAVIOLET RADIATION; UNITED STATES;

EID: 4644245739     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Fitzpatrick TB, Johnson R, Wolff K, et al. Color Atlas and Synopsis of Clinical Dermatology. 4th ed. Boston: McGrow-Hill; 2000.
2. Lui H, Mamelok A. Psoriasis, plaque. Emedicine Web site. Psoriasis, ploque. 2003. Available at: www.emedicine. com/derm/topic365.htm. Accessed July 25, 2004.
3. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581-588.
4. Swerlick R, Lowley T. Eczema, psoriasis, cutaneous infections, ocne, and other common skin disorders. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill. 2001:311-312.
5. Bowcock AM, Borker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol. 2003;49(suppl 2):S51-S56.
6. Shelley WB, Shelley ED. Psoriasis. In: Advanced Dermatologic Therapy II. 2nd ed. Toledo, OH: WB Sounders; 2001:924-972.
7. Lebwohl M. Psoriasis. In: Lebwohl MG, Heymonn W, Berth-Jones J, et al, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. New York: Mosby International; 2002:533-543.
8. Peters BP, Weissmann FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm. 2000;57:645-661.
9. Stern RS. Psoriasis. Lancet. 1997;350:349-353.
10. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999;107:595-605.
11. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furaate 0.1%-salicylic acid 5% ointment versus mometasone furaate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther. 1999;20:283-291.
12. Lebwohl M. The role of salicylic ocid in the treatment of psoriasis. Int J Dermatol. 1999;38:16-24.
13. Lebwohl M, Ali M. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-498.
14. Liem WH, McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis. 1995;55:306-310.
15. Katz HI. Topical carticasteroids. Dermatol Clin. 1995;13:805-815.
16. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121:63-67.
17. Lebwohl M, Abel E, Zanolli M, et ol. Topical therapy for psoriasis. Int J Dermatol. 1995;34:673-684.
18. Kotz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function. J Am Acod Dermatol. 1987;16:804-811.
19. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111:581-583.
20. Katz HI, Hien NT, Prawer SE, et al. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol. 1987;123:1308-1311.
21. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991;183:269-274.
22. Alpsoy E, Ozcan E, Cetin L, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol. 1998;38(2, pt 1):197-200.
23. Connetics Corporation. Products and Pipeline: Olux. Available at: http://www.connetics.com. Accessed June 1, 2004.
24. Kanzler MH, Gorsulowsky DC. Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. Br J Dermatol. 1993;129:310-314.
25. Thom SN, Lun KC, Cheang WK. A comparative study of calcipotriol ointment and tar in chronic plaque psariasis. Br J Dermatol. 1994;131:673-637.
26. Kanof NB, Blou S. Psoriasis: treatment with a new topical corticosteroid. Cutis. 1976;17:796-798.
27. Lynfield Y, Watsky M. Psoriasis: topical carticasteraid therapy. Cutis. 1976;18:133, 136-137.
28. Veronikis IE, Malabanan AO, Halick MF. Comparison of calcipotriene (Dovonex) with a coal tar emulsion (Exorex) in treating psoriasis in adults: a pilot study. Arch Dermatol. 1999;135:474-475.
29. Tzaneva S, Honigsmann H, Tanew A. Observer blind, randomized, intrapatient comparison of a navel 1% coal tar preparation (Exorex) and colcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol. 2003;149:350-353.
30. Smith CH, Jackson K, Chinn S, et al. A double blind, randomized, controlled clinical trial to assess the efficacy of a new caal tar preparation (Exarex) in the treatment of chronic, plaque type psoriasis. Clin Exp Dermatol. 2000;25:580-583.
31. Pittelkow MR, Perry HO, Muller SA, et al. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol. 1981;117:465-468.
32. Perry HO, Soderstrom CW, Schulze RW. The Gaeckerman treatment of psoriasis. Arch Dermatol. 1968;98:178-182.
33. Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, righ/left comparative, vehicle-contralled study. J Am Acad Dermatol. 1992;27(6, pt 1):983-938.
34. Perez A, Chen TC, Turner A, et al. Efficacy and safety of topical colcitrial (1,25dihydroxy vitamin D3) for the treatment of psoriasis. Br J Dermatol. 1996;134:238-246.
35. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Colcipotriene Study Group. J Am Acad Dermatol. 1995;32:67-72.
36. Kragballe K, Fogh K, Saggard H. Long-term efficacy and tolerability of topical calcipotrial in psoriasis. Results of an open study. Acta Derm Venereol. 1991;71:475-478.
37. Bruce S, Epinette WW, Funicella T, et al. Comparative study af calcipotriene (MC 903) ointment and fluocinanide ointment in the treatment of psoriasis. J Am Acad Dermatol. 1994;31(5, pt 1):755-759.
38. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alane for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2, pt 1):268-269.
39. Lebwahl M, Yales A, Lombordi K, et al. Calcipotriene ointment and halabetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39:447-450.
40. Georgiou S, Tsambaos D. Hypercalcaemia and hypercalciuria after topical treatment of psariasis with excessive amounts of calcipotriol. Acta Derm Venereol. 1999;79:86.
41. Mortensen L, Kragbolle K, Wegmann E, et al. Treatment of psoriasis vulgaris with topical calcipotriol has na short-term effect on calcium or bone metabolism: a randomized, dauble-blind, placebo-controlled study. Acta Derm Venereal. 1993;73:300-304.
42. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-cantrolled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37:85-92.
43. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus Twice-daily fluocinide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38 (5, pt 1):705-711.
44. Marks R. Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol. 1997;37(2, pt 3):S25-S32.
45. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4, pt 1):590-596.
46. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol. 2001;40:64-66.
47. Kaidbey K, Kopper SC, Sefton J, et al. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol. 2001;40:468-471.
48. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol. 2000;43(2, pt 3):S43-S46.
49. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol. 2002;46:907-913.
50. Ingram JT. The approach to psoriasis. Br Med J. 1953;4836:591-594.
51. Kragballe K, Fogh K, Sogaard H. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Results of an open study. Acta Derm Venereol. 1991;71:475-478.
52. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone volerate in treatment of psoriasis vulgaris [correction published in lancet. 1991;337:988]. Lancet. 1991;337:193-196.
53. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone volerate in treatment of psoriasis vulgaris [correction published in lancet. 1991;337:988]. Lancet. 1991;337:193-196.
54. Runne U, Kunze J. Short duration ('minutes') therapy with dithranol for psoriasis: a new out-patient regimen. Br J Dermatol. 1982;106:135-139.
55. Thune P, Brolund L. Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm Venereol Suppl (Stockh). 1992;172:28-29.